Dutasteride not for prostate cancer risk

THE 5-alpha reductase inhibitor (5-ARI) dutasteride is safe to use in benign prostatic hyperplasia (BPH), despite the bid for approval to use it to reduce prostate cancer risk being abandoned globally.

Dutasteride (Avodart) manufacturer GSK last week said it would not seek approval for the drug to be used to reduce the risk of prostate cancer, following a US Food and Drug Administration vote against a favourable risk/benefit profile for this indication.

The decision followed a review of data from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, which showed an increased number of high